Assessment of the impact of telehealth intervention in patients with bone and joint infection.

Adverse events Antibiotics Bone and joint infection Patient satisfaction Telehealth intervention

Journal

Infectious diseases now
ISSN: 2666-9919
Titre abrégé: Infect Dis Now
Pays: France
ID NLM: 101775152

Informations de publication

Date de publication:
03 Apr 2024
Historique:
received: 29 11 2023
revised: 27 03 2024
accepted: 29 03 2024
medline: 6 4 2024
pubmed: 6 4 2024
entrez: 5 4 2024
Statut: aheadofprint

Résumé

Patients with bone and joint infections (BJI) are involved in a complex care pathway and require prolonged antimicrobial treatment. Some studies have suggested that a pharmacist-led telehealth intervention (TI) could help to ensure better follow-up of chronic diseases. To our knowledge, there are no data on the effects of pharmacist-led TI on patients with BJI. The aim of this study is to assess the impact of a TI on patients treated for BJIs at three weeks after hospital discharge. Patients encountered during hospitalization and receiving standardized care including TI were included in the study. All adverse events (AE) reported by patients during TI were evaluated. Impact of pharmaceutical interventions (PIs) provided by a clinical pharmacist following TI was evaluated by CLEO© (CLinical, Economic and Organizational) scale. Patient satisfaction concerning TI was assessed by an anonymous questionnaire following medical consultation at the end of antimicrobial treatment. Over a 4-month period, 36 patients received TI. Fifty-two AEs were identified in 21 patients (58%). Two patients were hospitalized due to an AE. Clinical pharmacists provided 34 pharmaceutical interventions (PIs) for 23 patients (64%). According to CLEO scale, 11 PIs had a major clinical impact (32%), 6 PIs (18%) had a favorable impact on the direct cost of treatment and 27 PIs (79%) had positive organizational impact. Concerning TI process, patients were satisfied or very satisfied, with an average score of 9.6/10. TI led to a high number of pharmaceutical interventions (PIs), with a meaningful clinical, organizational, and economic impact. Patients were also highly satisfied with this intervention.

Identifiants

pubmed: 38580052
pii: S2666-9919(24)00061-7
doi: 10.1016/j.idnow.2024.104906
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104906

Informations de copyright

Copyright © 2024. Published by Elsevier Masson SAS.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Philippine Marque (P)

CHU de Bordeaux, Hôpital Pellegrin, Service de pharmacie clinique, Bordeaux, France.

Julie Leitao (J)

CHU de Bordeaux, Hôpital Pellegrin, Service de maladies infectieuses, Bordeaux, France.

Fréderic Dauchy (F)

CHU de Bordeaux, Hôpital Pellegrin, Service de maladies infectieuses, Bordeaux, France.

Olivier Gerbouin (O)

CHU de Bordeaux, Hôpital Pellegrin, Service de pharmacie clinique, Bordeaux, France.

Thierry Fabre (T)

CHU de Bordeaux, Hôpital Pellegrin, Service de chirurgie orthopédique, Bordeaux, France.

Fabien Xuereb (F)

CHU de Bordeaux, Hôpital Pellegrin, Service de pharmacie clinique, Bordeaux, France; Université de Bordeaux, INSERM, Biologie des maladies cardiovasculaires, U1034, F-33600 Pessac, France.

Marin Lahouati (M)

CHU de Bordeaux, Hôpital Pellegrin, Service de pharmacie clinique, Bordeaux, France; Université de Bordeaux, INSERM, Biologie des maladies cardiovasculaires, U1034, F-33600 Pessac, France. Electronic address: marin.lahouati@chu-bordeaux.fr.

Classifications MeSH